

## Consumer Healthcare turnover

Three months ended 30 June 2012

	Total		
	£m	CER%	AR%
<b>Turnover</b>			
Total wellness	486	(8)	(10)
Oral care	440	8	4
Nutrition	271	6	-
Skin health	60	(2)	(5)
Total	<u>1,257</u>	<u>5</u>	<u>(3)</u>

	Total		
	£m	CER%	AR%
<b>Turnover</b>			
US	220	(11)	(8)
Europe	457	(5)	(10)
ROW	580	10	5
Total	<u>1,257</u>	<u>5</u>	<u>(3)</u>

Six months ended 30 June 2012

	Total		
	£m	CER%	AR%
<b>Turnover</b>			
Total wellness	1,025	(8)	(10)
Oral care	902	9	6
Nutrition	540	8	3
Skin health	126	(4)	5
Total	<u>2,593</u>	<u>1</u>	<u>(2)</u>

	Total		
	£m	CER%	AR%
<b>Turnover</b>			
US	449	(9)	(7)
Europe	924	(4)	(8)
ROW	1,220	9	5
Total	<u>2,593</u>	<u>1</u>	<u>(2)</u>

**Pharmaceuticals and Vaccines turnover – Three months ended 30 June 2012**

	Total			USA			Europe			EMAP			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<b>Respiratory</b>	<b>1,814</b>	-	-	<b>838</b>	-	<b>4</b>	<b>483</b>	<b>(6)</b>	<b>(13)</b>	<b>213</b>	<b>10</b>	<b>7</b>	<b>280</b>	<b>8</b>	<b>11</b>
<i>Avamys/Veramyst</i>	64	3	-	15	(18)	(12)	20	5	(9)	16	6	-	13	33	44
<i>Flixonase/Flonase</i>	31	(3)	-	2	100	100	9	(18)	(18)	15	8	15	5	(17)	(17)
<i>Flixotide/Flovent</i>	189	(4)	(4)	107	(3)	1	31	(18)	(21)	14	27	27	37	-	(8)
<i>Seretide/Advair</i>	1,269	-	-	641	-	4	364	(4)	(11)	100	4	3	164	6	8
<i>Serevent</i>	38	(12)	(12)	13	8	8	16	(23)	(27)	-	-	-	9	(20)	(10)
<i>Ventolin</i>	147	(1)	(1)	57	(5)	-	30	(9)	(14)	44	13	10	16	-	(6)
<i>Xyzal</i>	32	100	>100	-	-	-	-	-	-	4	25	-	28	>100	>100
<i>Zyrtec</i>	18	(10)	(10)	-	-	-	-	-	-	8	33	33	10	(29)	(29)
Other*	26	13	8	3	>100	>100	13	(6)	(19)	12	15	(8)	(2)	-	(67)
<b>Anti-virals</b>	<b>197</b>	<b>(10)</b>	<b>(8)</b>	<b>13</b>	<b>(50)</b>	<b>(46)</b>	<b>20</b>	<b>(15)</b>	<b>(23)</b>	<b>87</b>	<b>(3)</b>	<b>(1)</b>	<b>77</b>	<b>(4)</b>	<b>1</b>
<i>Hepsera</i>	32	3	7	-	-	-	-	-	-	24	5	9	8	-	-
<i>Zovirax</i>	22	5	-	1	>100	>100	6	-	-	8	(10)	(20)	7	-	-
<i>Valtrex</i>	66	(24)	(23)	8	(64)	(64)	10	(23)	(23)	9	(10)	(10)	39	(7)	(5)
<i>Zeffix</i>	60	(6)	(3)	4	33	33	4	(17)	(33)	46	(6)	(2)	6	(17)	-
Other*	17	7	21	-	-	-	-	-	-	-	-	-	17	7	21
<b>Central nervous system</b>	<b>447</b>	<b>6</b>	<b>6</b>	<b>136</b>	<b>19</b>	<b>24</b>	<b>99</b>	<b>(13)</b>	<b>(20)</b>	<b>81</b>	<b>12</b>	<b>9</b>	<b>131</b>	<b>9</b>	<b>15</b>
<i>Imigran/Imitrex</i>	52	2	2	22	10	10	18	(5)	(5)	2	100	100	10	(9)	(9)
<i>Lamictal</i>	147	14	15	76	11	15	29	(6)	(12)	19	19	19	23	77	77
<i>Requip</i>	44	(23)	(23)	6	(40)	(40)	19	(28)	(41)	4	-	-	15	-	36
<i>Seroxat/Paxil</i>	112	3	5	-	-	-	15	(6)	(12)	22	16	16	75	(4)	-
<i>Treximet</i>	13	(14)	(7)	13	(14)	(7)	-	-	-	-	-	-	-	-	-
<i>Wellbutrin</i>	20	(9)	(13)	-	-	-	12	-	-	7	40	40	1	100	-
Other*	59	46	44	19	-	-	6	(30)	(40)	27	-	(7)	7	100	>100
<b>Cardiovascular and urogenital</b>	<b>572</b>	<b>(10)</b>	<b>(10)</b>	<b>327</b>	<b>(22)</b>	<b>(18)</b>	<b>129</b>	<b>2</b>	<b>(7)</b>	<b>72</b>	<b>16</b>	<b>14</b>	<b>44</b>	<b>26</b>	<b>29</b>
<i>Arixtra</i>	47	(36)	(37)	15	(66)	(63)	24	(4)	(8)	7	40	40	1	(33)	(67)
<i>Avodart</i>	197	6	5	81	(10)	(7)	58	13	5	20	11	11	38	43	36
<i>Coreg</i>	35	(13)	(10)	35	(11)	(8)	-	-	-	-	-	-	-	-	-
<i>Fraxiparine</i>	59	7	(2)	-	-	-	39	2	(7)	20	11	11	-	-	-
<i>Lovaza</i>	157	4	8	157	5	9	-	-	-	-	-	-	-	-	-
<i>Vesicare</i>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other*	77	(22)	(20)	39	(34)	(33)	8	(27)	(47)	25	18	14	5	(100)	>100
<b>Metabolic</b>	<b>45</b>	<b>(42)</b>	<b>(42)</b>	<b>(1)</b>	<b>&lt;(100)</b>	<b>&lt;(100)</b>	<b>7</b>	<b>(50)</b>	<b>(56)</b>	<b>17</b>	<b>13</b>	<b>13</b>	<b>22</b>	<b>(22)</b>	<b>(19)</b>
<i>Avandia products</i>	3	(85)	(88)	(2)	<(100)	<(100)	-	-	-	3	-	(25)	2	(75)	(50)
Other*	42	(21)	(19)	1	-	-	7	(56)	(61)	14	18	27	20	(13)	(13)
<b>Anti-bacterials</b>	<b>303</b>	<b>(5)</b>	<b>(9)</b>	<b>4</b>	<b>(75)</b>	<b>(75)</b>	<b>94</b>	<b>(16)</b>	<b>(23)</b>	<b>183</b>	<b>11</b>	<b>7</b>	<b>22</b>	<b>(4)</b>	<b>(8)</b>
<i>Augmentin</i>	149	11	5	-	-	-	48	(4)	(14)	90	18	13	11	29	57
Other*	154	(16)	(19)	4	(76)	(76)	46	(27)	(30)	93	4	2	11	(18)	(35)
<b>Oncology and emesis</b>	<b>196</b>	<b>23</b>	<b>21</b>	<b>81</b>	<b>39</b>	<b>45</b>	<b>61</b>	<b>5</b>	<b>(3)</b>	<b>30</b>	<b>41</b>	<b>36</b>	<b>24</b>	<b>14</b>	<b>14</b>
<i>Arzerra</i>	15	36	36	9	29	29	6	100	100	-	-	-	-	-	-
<i>Promacta</i>	30	76	76	13	50	63	8	60	60	3	>100	>100	6	>100	100
<i>Tyverb/Tykerb</i>	60	5	2	17	7	13	22	(11)	(19)	14	27	27	7	33	17
<i>Votrient</i>	39	77	77	20	67	67	14	100	75	4	>100	>100	1	<(100)	-
Other*	52	-	(2)	22	50	57	11	(40)	(45)	9	11	-	10	-	-
<b>Dermatology</b>	<b>210</b>	<b>(2)</b>	<b>(5)</b>	<b>59</b>	<b>(7)</b>	<b>(2)</b>	<b>35</b>	<b>(5)</b>	<b>(11)</b>	<b>96</b>	<b>4</b>	<b>(2)</b>	<b>20</b>	<b>(8)</b>	<b>(15)</b>
<i>Bactroban</i>	30	3	-	13	18	18	6	-	(14)	10	-	-	1	(50)	(50)
<i>Duac</i>	23	(12)	(8)	11	(8)	(15)	4	(17)	(33)	3	50	50	5	(50)	25
Other*	157	(1)	(5)	35	(14)	(3)	25	(4)	(6)	83	3	(3)	14	7	(20)
<b>Rare diseases</b>	<b>110</b>	-	-	<b>19</b>	<b>(25)</b>	<b>(21)</b>	<b>31</b>	<b>(6)</b>	<b>(11)</b>	<b>10</b>	<b>67</b>	<b>67</b>	<b>50</b>	<b>9</b>	<b>11</b>
<i>Flolan</i>	35	(27)	(22)	8	(11)	(11)	7	(36)	(36)	-	-	-	20	(28)	(20)
<i>Volibris</i>	31	45	41	-	-	-	18	12	6	2	-	-	11	>100	>100
Other*	44	5	2	11	(33)	(27)	6	-	(14)	8	33	33	19	33	27
<b>Other pharmaceuticals</b>	<b>202</b>	<b>(20)</b>	<b>(24)</b>	<b>3</b>	<b>(12)</b>	<b>(62)</b>	<b>37</b>	<b>(37)</b>	<b>(46)</b>	<b>103</b>	<b>(12)</b>	<b>(18)</b>	<b>59</b>	<b>(19)</b>	<b>(10)</b>
<i>Benlysta</i>	12	>100	>100	11	>100	>100	-	-	-	-	-	-	1	-	-
Other*	190	(24)	(28)	(8)	<(100)	<(100)	37	(38)	(46)	103	(12)	(18)	58	(19)	(11)
<b>Vaccines</b>	<b>763</b>	-	<b>(3)</b>	<b>183</b>	<b>(1)</b>	<b>3</b>	<b>240</b>	<b>(5)</b>	<b>(13)</b>	<b>277</b>	<b>15</b>	<b>9</b>	<b>63</b>	<b>(22)</b>	<b>(22)</b>
<i>Boostrix</i>	58	11	9	37	30	37	13	25	8	3	(25)	(25)	5	(40)	(50)
<i>Cervarix</i>	50	(22)	(23)	1	(50)	(50)	15	14	7	21	24	24	13	(59)	(59)
<i>Fluarix, FluLaval</i>	5	(38)	(38)	1	(80)	(80)	(2)	-	-	4	25	-	2	-	100
Hepatitis	165	(12)	(14)	68	(21)	(17)	52	(14)	(19)	36	19	16	9	(21)	(36)
<i>Infanrix, Pediarix</i>	179	19	15	54	68	74	91	-	(9)	22	77	69	12	(8)	-
<i>Rotarix</i>	93	25	24	22	(33)	(33)	10	10	-	47	60	57	14	>100	>100
<i>Synflorix</i>	101	10	2	-	-	-	11	8	(8)	90	17	8	-	-	-
Other*	112	(16)	(20)	-	-	-	50	(20)	(23)	54	(20)	(24)	8	50	33
	<b>4,859</b>	<b>(2)</b>	<b>(4)</b>	<b>1,662</b>	<b>(6)</b>	<b>(3)</b>	<b>1,236</b>	<b>(8)</b>	<b>(15)</b>	<b>1,169</b>	<b>9</b>	<b>5</b>	<b>792</b>	<b>-</b>	<b>4</b>
<b>ViiV Healthcare (HIV)</b>	<b>346</b>	<b>(7)</b>	<b>(9)</b>												
	<b>5,205</b>	<b>(3)</b>	<b>(4)</b>												

**Pharmaceuticals and Vaccines turnover – Six months ended 30 June 2012**

	Total			USA			Europe			EMAP			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<b>Respiratory</b>	<b>3,655</b>	<b>1</b>	<b>1</b>	<b>1,686</b>	<b>3</b>	<b>5</b>	<b>984</b>	<b>(5)</b>	<b>(10)</b>	<b>411</b>	<b>10</b>	<b>7</b>	<b>574</b>	<b>-</b>	<b>3</b>
<i>Avamys/Veramyst</i>	133	(1)	(2)	29	(13)	(9)	37	5	(3)	29	15	12	38	(8)	(5)
<i>Flixonase/Flonase</i>	73	(9)	(8)	9	-	-	17	(10)	(15)	26	9	13	21	(38)	(34)
<i>Flixotide/Flovent</i>	388	(3)	(3)	220	1	3	65	(14)	(18)	27	4	4	76	(4)	(5)
<i>Seretide/Advair</i>	2,521	1	1	1,271	3	6	739	(4)	(8)	198	6	5	313	2	5
<i>Serevent</i>	76	(20)	(20)	26	(21)	(21)	33	(20)	(25)	1	-	-	16	(18)	(6)
<i>Ventolin</i>	302	3	2	126	9	12	63	(7)	(11)	85	10	8	28	(16)	(13)
<i>Xyzal</i>	68	>100	>100	-	-	-	-	-	-	8	29	14	60	>100	>100
<i>Zyrtec</i>	42	(20)	(18)	-	-	-	-	-	-	17	31	31	25	(37)	(34)
Other*	52	10	4	5	(25)	25	30	-	(3)	20	21	5	(3)	(50)	(25)
<b>Anti-virals</b>	<b>381</b>	<b>(14)</b>	<b>(12)</b>	<b>24</b>	<b>(62)</b>	<b>(61)</b>	<b>42</b>	<b>(14)</b>	<b>(18)</b>	<b>172</b>	<b>2</b>	<b>4</b>	<b>143</b>	<b>(13)</b>	<b>(9)</b>
<i>Hepsera</i>	61	2	5	-	-	-	-	-	-	46	2	7	15	-	-
<i>Zovirax</i>	46	(19)	(21)	2	(80)	(80)	12	(8)	(8)	17	6	-	15	(17)	(17)
<i>Valtrex</i>	129	(28)	(27)	15	(66)	(66)	20	(16)	(20)	17	(6)	(6)	77	(18)	(13)
<i>Zeffix</i>	118	(3)	-	6	(14)	(14)	9	(17)	(25)	91	-	5	12	(8)	-
Other*	27	8	13	1	-	-	1	-	-	1	-	-	24	-	4
<b>Central nervous system</b>	<b>848</b>	<b>3</b>	<b>4</b>	<b>260</b>	<b>19</b>	<b>22</b>	<b>201</b>	<b>(13)</b>	<b>(17)</b>	<b>155</b>	<b>6</b>	<b>4</b>	<b>232</b>	<b>4</b>	<b>9</b>
<i>Imigran/Imitrex</i>	96	(6)	(6)	37	(10)	(10)	35	-	(3)	3	-	-	21	(9)	(5)
<i>Lamictal</i>	295	21	22	160	31	34	58	(8)	(12)	36	6	6	41	74	78
<i>Requip</i>	89	(18)	(19)	15	(25)	(25)	40	(29)	(35)	7	-	-	27	14	29
<i>Seroxat/Paxil</i>	203	(6)	(3)	-	-	-	29	(6)	(12)	42	-	-	132	(9)	(4)
<i>Treximet</i>	25	(14)	(11)	25	(14)	(11)	-	-	-	-	-	-	-	-	-
<i>Wellbutrin</i>	40	(2)	(5)	4	(50)	(50)	22	5	-	13	40	30	1	(100)	(50)
Other*	100	24	20	19	-	-	17	(29)	(29)	54	6	2	10	100	67
<b>Cardiovascular and urogenital</b>	<b>1,300</b>	<b>10</b>	<b>10</b>	<b>819</b>	<b>9</b>	<b>11</b>	<b>260</b>	<b>5</b>	<b>(2)</b>	<b>140</b>	<b>21</b>	<b>20</b>	<b>81</b>	<b>27</b>	<b>31</b>
<i>Arixtra</i>	95	(35)	(36)	31	(65)	(64)	48	-	(4)	13	44	44	3	(20)	(40)
<i>Avodart</i>	383	9	8	157	(6)	(4)	113	13	8	40	24	21	73	36	38
<i>Coreg</i>	70	(11)	(8)	70	(9)	(7)	-	-	-	-	-	-	-	-	-
<i>Fraxiparine</i>	120	11	5	-	-	-	80	6	(1)	40	21	21	-	-	-
<i>Lovaza</i>	308	10	13	307	11	14	-	-	-	-	-	-	1	(50)	(50)
<i>Vesicare</i>	174	>100	>100	174	>100	>100	-	-	-	-	-	-	-	-	-
Other*	150	(2)	(2)	80	(2)	(1)	19	(24)	(34)	47	12	12	4	100	>100
<b>Metabolic</b>	<b>78</b>	<b>(51)</b>	<b>(52)</b>	<b>(13)</b>	<b>&lt;(100)</b>	<b>&lt;(100)</b>	<b>13</b>	<b>(52)</b>	<b>(58)</b>	<b>32</b>	<b>10</b>	<b>7</b>	<b>46</b>	<b>(20)</b>	<b>(16)</b>
<i>Avandia products</i>	(5)	<(100)	<(100)	(14)	<(100)	<(100)	-	-	-	5	(25)	(38)	4	(70)	(60)
Other*	83	(17)	(17)	1	-	-	13	(55)	(61)	27	23	23	42	(9)	(7)
<b>Anti-bacterials</b>	<b>621</b>	<b>(10)</b>	<b>(13)</b>	<b>10</b>	<b>(71)</b>	<b>(71)</b>	<b>215</b>	<b>(18)</b>	<b>(23)</b>	<b>354</b>	<b>4</b>	<b>1</b>	<b>42</b>	<b>(15)</b>	<b>(13)</b>
<i>Augmentin</i>	302	(4)	(8)	-	-	-	110	(10)	(16)	173	1	(3)	19	-	6
Other*	319	(14)	(17)	10	(70)	(70)	105	(25)	(29)	181	8	5	23	(23)	(23)
<b>Oncology and emesis</b>	<b>375</b>	<b>22</b>	<b>21</b>	<b>151</b>	<b>29</b>	<b>32</b>	<b>123</b>	<b>9</b>	<b>3</b>	<b>59</b>	<b>53</b>	<b>48</b>	<b>42</b>	<b>11</b>	<b>14</b>
<i>Arzerra</i>	27	35	35	18	29	29	9	50	50	-	-	-	-	-	-
<i>Promacta</i>	57	97	97	24	64	71	16	89	78	5	>100	>100	12	>100	>100
<i>Tyverb/Tykerb</i>	120	10	8	34	18	21	45	(6)	(12)	27	47	42	14	-	8
<i>Votrient</i>	72	87	85	36	50	50	27	>100	>100	8	>100	>100	1	(100)	-
Other*	99	(10)	(11)	39	(9)	15	26	(33)	(35)	19	5	-	15	(11)	(17)
<b>Dermatology</b>	<b>423</b>	<b>(1)</b>	<b>(3)</b>	<b>118</b>	<b>(7)</b>	<b>(4)</b>	<b>74</b>	<b>-</b>	<b>(5)</b>	<b>191</b>	<b>7</b>	<b>2</b>	<b>40</b>	<b>(18)</b>	<b>(17)</b>
<i>Bactroban</i>	60	5	3	24	9	9	13	-	(7)	19	11	6	4	(25)	-
<i>Duac</i>	51	(4)	(4)	27	(7)	(7)	11	-	(8)	6	17	-	7	(17)	17
Other*	312	(1)	(4)	67	(11)	(7)	50	-	(4)	166	7	1	29	(18)	(24)
<b>Rare diseases</b>	<b>216</b>	<b>(3)</b>	<b>(2)</b>	<b>41</b>	<b>(20)</b>	<b>(18)</b>	<b>63</b>	<b>(10)</b>	<b>(14)</b>	<b>19</b>	<b>19</b>	<b>19</b>	<b>93</b>	<b>10</b>	<b>13</b>
<i>Flolan</i>	70	(26)	(24)	16	(16)	(16)	14	(44)	(44)	-	-	-	40	(21)	(17)
<i>Volibris</i>	59	36	34	-	-	-	36	12	6	4	100	100	19	>100	>100
Other*	87	2	2	25	(23)	(19)	13	-	(7)	15	7	7	34	31	31
<b>Other pharmaceuticals</b>	<b>411</b>	<b>(12)</b>	<b>(16)</b>	<b>19</b>	<b>83</b>	<b>58</b>	<b>91</b>	<b>(24)</b>	<b>(31)</b>	<b>201</b>	<b>(10)</b>	<b>(15)</b>	<b>100</b>	<b>(13)</b>	<b>(7)</b>
<i>Benlysta</i>	21	>100	>100	19	>100	>100	1	-	-	-	-	-	1	-	-
Other*	390	(16)	(20)	-	-	-	90	(26)	(32)	201	(10)	(15)	99	(13)	(8)
<b>Vaccines</b>	<b>1,521</b>	<b>-</b>	<b>(2)</b>	<b>331</b>	<b>(3)</b>	<b>(1)</b>	<b>465</b>	<b>(4)</b>	<b>(10)</b>	<b>487</b>	<b>3</b>	<b>(1)</b>	<b>238</b>	<b>12</b>	<b>16</b>
<i>Boostrix</i>	105	25	24	58	33	38	25	29	19	8	33	33	14	(6)	(13)
<i>Cervarix</i>	181	2	4	2	(33)	(33)	29	7	-	34	(13)	(13)	116	8	13
<i>Fluarix, FluLaval</i>	12	(29)	(29)	1	(83)	(83)	(2)	-	-	8	-	(11)	5	-	25
Hepatitis	318	(8)	(9)	131	(16)	(14)	100	(11)	(15)	61	29	24	26	(10)	(13)
<i>Infanrix, Pediarix</i>	340	10	7	91	25	28	183	2	(4)	36	19	16	30	17	25
<i>Rotarix</i>	169	12	11	48	(22)	(20)	20	5	-	75	13	12	26	>100	>100
<i>Synflorix</i>	174	5	(1)	-	-	-	20	(12)	(20)	151	8	2	3	(33)	-
Other*	222	(16)	(19)	-	-	-	90	(18)	(21)	114	(16)	(19)	18	(14)	(14)
	<b>9,829</b>	<b>-</b>	<b>(1)</b>	<b>3,446</b>	<b>1</b>	<b>4</b>	<b>2,531</b>	<b>(7)</b>	<b>(12)</b>	<b>2,221</b>	<b>6</b>	<b>3</b>	<b>1,631</b>	<b>-</b>	<b>4</b>
<b>ViiV Healthcare (HIV)</b>	<b>680</b>	<b>(6)</b>	<b>(7)</b>												
	<b>10,509</b>	<b>(1)</b>	<b>(1)</b>												

**ViiV Healthcare turnover**  
**Three months ended 30 June 2012**

	Total			USA			Europe			EMAP			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<i>Combivir</i>	49	(28)	(31)	5	(84)	(83)	17	(25)	(31)	24	>100	90	3	(28)	(20)
<i>Epivir</i>	14	(48)	(52)	2	(81)	(80)	6	(25)	(30)	5	(53)	(55)	1	(7)	(21)
<i>Epzicom/Kivexa</i>	166	16	13	59	7	12	70	11	3	16	85	79	21	21	20
<i>Lexiva</i>	33	(14)	(11)	18	(3)	1	8	(20)	(27)	3	(25)	(26)	4	(34)	19
<i>Selzentry</i>	31	23	19	14	36	41	14	13	5	1	67	60	2	10	(9)
<i>Trizivir</i>	29	(6)	(6)	15	(15)	(12)	10	(17)	(23)	3	>100	>100	1	>100	>100
<i>Other*</i>	24	(34)	(37)	8	(56)	(53)	5	(26)	(31)	8	20	16	3	(42)	(63)
	<b>346</b>	<b>(7)</b>	<b>(9)</b>	<b>121</b>	<b>(25)</b>	<b>(22)</b>	<b>130</b>	<b>(4)</b>	<b>(11)</b>	<b>60</b>	<b>42</b>	<b>36</b>	<b>35</b>	<b>2</b>	<b>2</b>

**Six months ended 30 June 2012**

	Total			USA			Europe			EMAP			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<i>Combivir</i>	83	(39)	(42)	9	(87)	(85)	35	(29)	(33)	33	62	57	6	(22)	(33)
<i>Epivir</i>	27	(49)	(51)	4	(80)	(80)	12	(24)	(29)	7	(42)	(42)	4	(33)	(33)
<i>Epzicom/Kivexa</i>	325	15	13	119	12	14	142	12	7	25	53	47	39	18	18
<i>Lexiva</i>	64	(7)	(7)	35	(3)	-	18	(21)	(25)	6	(14)	(14)	5	67	67
<i>Selzentry</i>	60	24	22	27	30	35	28	16	12	1	100	-	4	33	33
<i>Trizivir</i>	56	(8)	(8)	30	(6)	(6)	20	(15)	(23)	3	>100	>100	3	(50)	50
<i>Other*</i>	65	(6)	(6)	35	(6)	(3)	13	(7)	(7)	13	18	18	4	(38)	(50)
	<b>680</b>	<b>(6)</b>	<b>(7)</b>	<b>259</b>	<b>(18)</b>	<b>(16)</b>	<b>268</b>	<b>(3)</b>	<b>(8)</b>	<b>88</b>	<b>30</b>	<b>26</b>	<b>65</b>	<b>2</b>	<b>2</b>

\* All other product sales totalled £954 million and declined 12% CER and 15 % AR in the quarter.

\* All other product sales totalled £1,906 million and declined 9% CER and 11% AR in the half-year.